Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Inclusion Criteria: * relapsed or refractory disease * histologically or cytologically confirmed disease * characteristic immunophenotypic profiles * measurable disease (for lymphoma patients) * ECOG performance status of 0-2 * adequate liver and kidney function * adequate bone marrow reserves * ineligible or unwilling to undergo autologous stem cell transplantation Exclusion Criteria: * failure to recover from any major surgery within 4 weeks of study entry * pregnant or lactating women * women of child-bearing potential not using reliable and appropriate contraception * routine prophylactic use of G-CSF required within 2 weeks of study entry * Grade 3 or higher peripheral neuropathy * history of hepatitis B virus or HIV * central nervous system or meningeal involvement by lymphoma or multiple myeloma